Literature DB >> 10590376

Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder.

N Fleshner1, J Garland, A Moadel, H Herr, J Ostroff, R Trambert, M O'Sullivan, P Russo.   

Abstract

BACKGROUND: The aim of this study was to assess the influence of tobacco exposure, at the time of diagnosis, on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma (TCC) of the bladder.
METHODS: A retrospective cohort study was performed using the MSKCC Registry to identify all institutional cases of "noninvasive" TCC (n = 1632) between 1985 and 1995. After employing exclusion criteria, 286 cases of incident tobacco-associated superficial TCC were divided into 3 strata of tobacco exposure (127 ex-smokers, 51 quitters, and 108 continued smokers) by chart review and post hoc questionnaires (n = 82). Measured outcomes included recurrence free survival and survival free of adverse events (defined a priori as disease progression or other urinary tract TCC).
RESULTS: There were no significant differences among ex-smokers, quitters, and continued smokers in terms of stage, grade, tumor size, multifocality, up-front bacillus Calmette-Guérin therapy, or median follow-up. Ex-smokers presented at a later age than individuals who continued to smoke. Post hoc questionnaires and chart reviews were compared in terms of smoking status at time of diagnosis, and reliability was excellent (kappa = 0.89). Multivariate analyses revealed diminished recurrence free survival among continued smokers versus quitters or ex-smokers. Univariate analyses revealed diminished adverse event free survival among continued smokers versus quitters or ex-smokers. Multivariate models assessing adverse event free survival revealed a similar trend (P = 0.06).
CONCLUSIONS: Continued smokers experience worse disease-associated outcomes than patients who quit smoking. Smoking cessation should thus be employed as a tertiary prevention strategy for patients with superficial TCC. Copyright 1999 American Cancer Society.

Entities:  

Mesh:

Year:  1999        PMID: 10590376

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  41 in total

1.  [Does cigarette smoking influence the survival of patients with prostate cancer?].

Authors:  T Jäger; A Eisenhardt; H Rübben; G Lümmen
Journal:  Urologe A       Date:  2007-04       Impact factor: 0.639

Review 2.  Chemoprevention of bladder cancer.

Authors:  Dragan J Golijanin; David Kakiashvili; Ralph R Madeb; Edward M Messing; Seth P Lerner
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

Review 3.  Lifestyle and nutritional modifiable factors in the prevention and treatment of bladder cancer.

Authors:  Marilyn L Kwan; Brandon Garren; Matthew E Nielsen; Li Tang
Journal:  Urol Oncol       Date:  2018-04-25       Impact factor: 3.498

4.  Body mass and smoking are modifiable risk factors for recurrent bladder cancer.

Authors:  Asaf Wyszynski; Sam A Tanyos; Judy R Rees; Carmen J Marsit; Karl T Kelsey; Alan R Schned; Eben M Pendleton; Maria O Celaya; Michael S Zens; Margaret R Karagas; Angeline S Andrew
Journal:  Cancer       Date:  2013-10-10       Impact factor: 6.860

5.  Prognostic impact of VEGF and VEGF receptor 1 (FLT1) expression in patients irradiated for stage II/III non-small cell lung cancer (NSCLC).

Authors:  Dirk Rades; Cornelia Setter; Juergen Dunst; Olav Dahl; Steven E Schild; Frank Noack
Journal:  Strahlenther Onkol       Date:  2010-04-26       Impact factor: 3.621

6.  Association study of the G-protein beta3 subunit C825T polymorphism with disease progression in patients with bladder cancer.

Authors:  Andreas Eisenhardt; Winfried Siffert; Dieter Rosskopf; Michael Musch; Max Mosters; Ulla Roggenbuck; Karl-Heinz Jöckel; Herbert Rübben; Gerd Lümmen
Journal:  World J Urol       Date:  2005-11-08       Impact factor: 4.226

Review 7.  Tobacco use and cessation for cancer survivors: an overview for clinicians.

Authors:  Maher Karam-Hage; Paul M Cinciripini; Ellen R Gritz
Journal:  CA Cancer J Clin       Date:  2014-05-09       Impact factor: 508.702

8.  Integrating tobacco treatment into cancer care: Study protocol for a randomized controlled comparative effectiveness trial.

Authors:  Elyse R Park; Jamie S Ostroff; Giselle K Perez; Kelly A Hyland; Nancy A Rigotti; Sarah Borderud; Susan Regan; Alona Muzikansky; Emily R Friedman; Douglas E Levy; Susan Holland; Justin Eusebio; Lisa Peterson; Julia Rabin; Jacob Miller-Sobel; Irina Gonzalez; Laura Malloy; Maureen O'Brien; Suhana de León-Sanchez; C Will Whitlock
Journal:  Contemp Clin Trials       Date:  2016-07-19       Impact factor: 2.226

9.  Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy.

Authors:  Michael Rink; Evanguelos Xylinas; Vitaly Margulis; Eugene K Cha; Behfar Ehdaie; Jay D Raman; Felix K Chun; Kazumasa Matsumoto; Yair Lotan; Helena Furberg; Marek Babjuk; Armin Pycha; Christopher G Wood; Pierre I Karakiewicz; Margit Fisch; Douglas S Scherr; Shahrokh F Shariat
Journal:  Eur Urol       Date:  2012-06-22       Impact factor: 20.096

10.  DNA damage in exfoliated cells and histopathological alterations in the urinary tract of mice exposed to cigarette smoke and treated with chemopreventive agents.

Authors:  Sebastiano La Maestra; Rosanna T Micale; Silvio De Flora; Francesco D'Agostini; Gancho Ganchev; Marietta Iltcheva; Nikolay Petkov; Vernon E Steele; Roumen Balansky
Journal:  Carcinogenesis       Date:  2012-10-05       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.